Pro-resolving lipid mediator lipoxin A4 attenuates neuro-inflammation by modulating T cell responses and modifies the spinal cord lipidome
CD Troletti, G Enzmann, V Chiurchiù, A Kamermans… - Cell reports, 2021 - cell.com
The chronic neuro-inflammatory character of multiple sclerosis (MS) suggests that the
natural process to resolve inflammation is impaired. This protective process is orchestrated
by specialized pro-resolving lipid mediators (SPMs), but to date, the role of SPMs in MS
remains largely unknown. Here, we provide in vivo evidence that treatment with the SPM
lipoxin A 4 (LXA 4) ameliorates clinical symptoms of experimental autoimmune
encephalomyelitis (EAE) and inhibits CD4+ and CD8+ T cell infiltration into the central …
natural process to resolve inflammation is impaired. This protective process is orchestrated
by specialized pro-resolving lipid mediators (SPMs), but to date, the role of SPMs in MS
remains largely unknown. Here, we provide in vivo evidence that treatment with the SPM
lipoxin A 4 (LXA 4) ameliorates clinical symptoms of experimental autoimmune
encephalomyelitis (EAE) and inhibits CD4+ and CD8+ T cell infiltration into the central …
Pro-resolving lipid mediator lipoxin A4 attenuates neuro-inflammation by modulating T cell responses and modifies the spinal cord lipidome.
G Enzmann, V Chiurchiù, A Kamermans, SM Tietz… - Cell Reports, 2021 - europepmc.org
The chronic neuro-inflammatory character of multiple sclerosis (MS) suggests that the
natural process to resolve inflammation is impaired. This protective process is orchestrated
by specialized pro-resolving lipid mediators (SPMs), but to date, the role of SPMs in MS
remains largely unknown. Here, we provide in vivo evidence that treatment with the SPM
lipoxin A 4 (LXA 4) ameliorates clinical symptoms of experimental autoimmune
encephalomyelitis (EAE) and inhibits CD4+ and CD8+ T cell infiltration into the central …
natural process to resolve inflammation is impaired. This protective process is orchestrated
by specialized pro-resolving lipid mediators (SPMs), but to date, the role of SPMs in MS
remains largely unknown. Here, we provide in vivo evidence that treatment with the SPM
lipoxin A 4 (LXA 4) ameliorates clinical symptoms of experimental autoimmune
encephalomyelitis (EAE) and inhibits CD4+ and CD8+ T cell infiltration into the central …
以上显示的是最相近的搜索结果。 查看全部搜索结果